These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 27853808)

  • 1. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
    van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
    PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Voccia I; Tang W; Schulman S
    J Thromb Thrombolysis; 2022 Feb; 53(2):399-409. PubMed ID: 34453675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Black SA; Cohen AT
    Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants and venous thromboembolism.
    Franchini M; Mannucci PM
    Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Goldhaber SZ; Schulman S; Eriksson H; Feuring M; Fraessdorf M; Kreuzer J; Schüler E; Schellong S; Kakkar A
    Thromb Haemost; 2017 Nov; 117(11):2045-2052. PubMed ID: 29202209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
    Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
    JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
    Goldhaber SZ; Eriksson H; Kakkar A; Schellong S; Feuring M; Fraessdorf M; Kreuzer J; Schueler E; Schulman S
    Vasc Med; 2016 Dec; 21(6):506-514. PubMed ID: 27807306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Goldhaber SZ; Schellong S; Kakkar A; Eriksson H; Feuring M; Kreuzer J; Fraessdorf M; Schulman S
    Thromb Haemost; 2016 Sep; 116(4):714-21. PubMed ID: 27411591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.